Should You Worry About Novavax's Vaccine Delay?

Investors expect Novavax (NASDAQ: NVAX) to file for Emergency Use Authorization for its coronavirus vaccine candidate soon. But the filing won't come as soon as everyone had hoped. In this Motley Fool Live video recorded on May 28, 2021, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss whether the recently announced delay in Novavax's filing might hurt eventual vaccine sales.

Continue reading

Source Fool.com